Ignite Creation Date:
2025-12-25 @ 12:19 AM
Ignite Modification Date:
2026-04-22 @ 7:02 AM
Study NCT ID:
NCT02795858
Status:
COMPLETED
Last Update Posted:
2025-02-19
First Post:
2016-06-07
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
Sponsor:
Dana-Farber Cancer Institute
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-06-14
Start Date Type:
ACTUAL
Primary Completion Date:
2022-12-31
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-12-31
Completion Date Type:
ACTUAL
First Submit Date:
2016-06-07
First Submit QC Date:
None
Study First Post Date:
2016-06-10
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2024-01-03
Results First Submit QC Date:
None
Results First Post Date:
2024-03-05
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-02-04
Last Update Post Date:
2025-02-19
Last Update Post Date Type:
ACTUAL